IDEXX Laboratories Inc - Asset Resilience Ratio
IDEXX Laboratories Inc (IDXX) has an Asset Resilience Ratio of -5.55% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check IDXX strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2018)
This chart shows how IDEXX Laboratories Inc's Asset Resilience Ratio has changed over time. See IDXX equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down IDEXX Laboratories Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see IDEXX Laboratories Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $-185.87 Million | -5.55% |
| Total Liquid Assets | $-185.87 Million | -5.55% |
Asset Resilience Insights
- Limited Liquidity: IDEXX Laboratories Inc maintains only -5.55% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
IDEXX Laboratories Inc Industry Peers by Asset Resilience Ratio
Compare IDEXX Laboratories Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fleury S.A.
SA:FLRY3 |
Diagnostics & Research | 16.06% |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716 |
Diagnostics & Research | 0.12% |
|
Spectral Med Inc
TO:EDT |
Diagnostics & Research | 11.67% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Genetic Signatures Ltd
AU:GSS |
Diagnostics & Research | 60.91% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for IDEXX Laboratories Inc (2000–2018)
The table below shows the annual Asset Resilience Ratio data for IDEXX Laboratories Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 0.00% | $0.00 | $1.54 Billion | -- |
| 2017-12-31 | 16.59% | $284.25 Million | $1.71 Billion | +1.11pp |
| 2016-12-31 | 15.48% | $236.95 Million | $1.53 Billion | +1.00pp |
| 2015-12-31 | 14.48% | $213.59 Million | $1.47 Billion | -- |
| 2014-12-31 | 0.00% | $0.00 | $1.38 Billion | -- |
| 2013-12-31 | 0.00% | $0.00 | $1.23 Billion | -- |
| 2012-12-31 | 0.00% | $0.00 | $1.10 Billion | -- |
| 2011-12-31 | 0.00% | $0.00 | $1.03 Billion | -- |
| 2010-12-31 | 0.00% | $0.00 | $897.14 Million | -- |
| 2006-12-31 | 6.25% | $35.00 Million | $559.56 Million | -7.11pp |
| 2005-12-31 | 13.37% | $65.58 Million | $490.68 Million | -4.16pp |
| 2004-12-31 | 17.52% | $90.12 Million | $514.24 Million | +11.01pp |
| 2003-12-31 | 6.51% | $33.99 Million | $521.88 Million | -1.50pp |
| 2002-12-31 | 8.02% | $33.40 Million | $416.65 Million | +4.56pp |
| 2001-12-31 | 3.46% | $12.89 Million | $373.11 Million | -5.24pp |
| 2000-12-31 | 8.69% | $29.20 Million | $335.80 Million | -- |
About IDEXX Laboratories Inc
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urin… Read more